BeOne Medicines (BEIGF) Research & Development (2015 - 2026)

BeOne Medicines (BEIGF) has reported Research & Development for 12 consecutive years, with $612.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 16.65% year-over-year to $612.3 million in Q2 2026; TTM through Jun 2026 was $2.3 billion, a 12.11% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 9.86% from the prior year.
• Research & Development was $612.3 million for Q2 2026 at BeOne Medicines, up from $541.2 million in the prior quarter.
• Over five years, Research & Development peaked at $615.4 million in Q4 2025 and troughed at $378.2 million in Q2 2022.
• A 5-year average of $481.8 million and a median of $471.3 million in 2024 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 21.57% in 2022, down 3.61% in 2022.
• Over 5 years, Research & Development stood at $446.0 million in 2022, then rose by 10.75% to $494.0 million in 2023, then climbed by 9.72% to $542.0 million in 2024, then advanced by 13.54% to $615.4 million in 2025, then fell by 0.51% to $612.3 million in 2026.
• The last three Research & Development figures came in at $612.3 million (Q2 2026), $541.2 million (Q1 2026), and $615.4 million (Q4 2025), per Business Quant data.